相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Incidence of and risk factors associated with lung metastases in newly diagnosed epithelial ovarian cancer with a look on prognosis after diagnosis: a population-based cohort study of the SEER database
Jiaqin Xu et al.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS (2021)
Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy
Yasmin A. Lyons et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2020)
Ultra-radical upfront surgery does not improve survival in women with advanced epithelial ovarian cancer; a natural experiment in a complete population
Henrik Falconer et al.
GYNECOLOGIC ONCOLOGY (2020)
Impact of residual disease on overall survival in women with Federation of Gynecology and Obstetrics stage IIIB-IIIC vs stage IV epithelial ovarian cancer after primary surgery
Sarah M. Sorensen et al.
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA (2019)
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
A. Gonzalez-Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
I. Ray-Coquard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Perioperative events influence cancer recurrence risk after surgery
Jonathan G. Hiller et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Sites of distant metastases and overall survival in ovarian cancer: A study of 1481 patients
Kui Deng et al.
GYNECOLOGIC ONCOLOGY (2018)
Continuous improvement in primary Debulking surgery for advanced ovarian cancer: Do increased complete gross resection rates independently lead to increased progression-free and overall survival?
Jill H. Tseng et al.
GYNECOLOGIC ONCOLOGY (2018)
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
K. Moore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Lymph node metastases as only qualifier for stage IV serous ovarian cancer confers longer survival than other sites of distant disease - a Swedish Gynecologic Cancer Group (SweGCG) study
Elisabet Hjerpe et al.
ACTA ONCOLOGICA (2018)
Appropriate Recommendations for Surgical Debulking in Stage IV Ovarian Cancer
Jing-Yi Chern et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2016)
FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisited
Beyhan Ataseven et al.
GYNECOLOGIC ONCOLOGY (2016)
Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV
Beyhan Ataseven et al.
GYNECOLOGIC ONCOLOGY (2016)
Minimal Macroscopic Residual Disease (0.1-1 cm). Is It Still a Surgical Goal in Advanced Ovarian Cancer?
Luis M. Chiva et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2016)
European Society of Gynaecologic Oncology Quality Indicators for Advanced Ovarian Cancer Surgery
Denis Querleu et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2016)
Does Aggressive Surgery Improve Outcomes? Interaction Between Preoperative Disease Burden and Complex Surgery in Patients With Advanced-Stage Ovarian Cancer: An Analysis of GOG 182
Neil S. Horowitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Role of aggressive surgical cytoreduction in advanced ovarian cancer
Suk-Joon Chang et al.
JOURNAL OF GYNECOLOGIC ONCOLOGY (2015)
Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: A meta-analysis
Suk-Joon Chang et al.
GYNECOLOGIC ONCOLOGY (2013)
An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT)
Dennis S. Chi et al.
GYNECOLOGIC ONCOLOGY (2012)
Maximal Cytoreduction in Patients With FIGO Stage IIIC to Stage IV Ovarian, Fallopian, and Peritoneal Cancer in Day-to-Day Practice A Retrospective French Multicentric Study
Mathieu Luyckx et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2012)
The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: A gynecologic oncology group study
Chad A. Hamilton et al.
GYNECOLOGIC ONCOLOGY (2011)
Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer
Philipp Harter et al.
GYNECOLOGIC ONCOLOGY (2011)
Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)
Gordon John Sampson Rustin et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2011)
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Timothy J. Perren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Influence of Residual Tumor on Outcome in Ovarian Cancer Patients With FIGO Stage IV Disease
Pauline Wimberger et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
The Clavien-Dindo Classification of Surgical Complications Five-Year Experience
Pierre A. Clavien et al.
ANNALS OF SURGERY (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm
Dennis S. Chi et al.
GYNECOLOGIC ONCOLOGY (2009)
The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer
Eric L. Eisenhauer et al.
GYNECOLOGIC ONCOLOGY (2006)
分享论文
